GHR Foundation
  • Domains of Work
    • Global >
      • Children in Families
      • Prepare The Future
    • Local >
      • Catholic Education
      • Twin Cities Racial Equity (TCRE)
    • Biomedical >
      • Alzheimer's Initiative
  • News
  • About Us
    • The Foundation
    • History & Legacy
    • Team >
      • Staff
      • Committees
      • Board
    • Programs in Transition >
      • BridgeBuilder >
        • Overview
        • 2017 Top Ideas >
          • Peace Direct
          • BioCarbon Engineering
          • LIFT Chicago
          • Local Youth Corner Cameroon
          • NaTakallam
        • 2018 Top Ideas >
          • This is My Backyard
          • Found in Translation
          • Producers Direct
          • War Child Canada
          • My Choices Foundation
        • 2019 Top Ideas >
          • Top Manta
          • Five One Labs
          • SAMA for All
          • Talent Beyond Boundaries
          • FaithAction
      • Inter-Religious Action
      • Sister Support
    • FAQs
    • Grants & Financials
  • Contact

GHR Partner C2N Diagnostics Launches Breakthrough Alzheimer's Blood Test

10/29/2020

0 Comments

 
Picture
C2N Diagnostics’ Alzheimer's blood test has been introduced into the clinic, a breakthrough healthcare innovation for patients, advocates, and physicians who have long awaited an easy to administer test that can help them better understand Alzheimer’s disease.

C2N developed this groundbreaking test based upon longtime GHR partner Dr. Randall Bateman’s initial discovery of how to measure amyloid proteins in blood, validating its results in a clinical trial of 686 patients. Earlier this year, GHR made a Program-Related Investment (PRI) in C2N to provide the resources necessary to develop and launch this innovation. 

The test is a highly sensitive blood test using mass spectrometry and is performed in C2N’s CLIA-certified lab. While the test by itself cannot diagnose Alzheimer’s disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process. 

Joel B. Braunstein, MD, CEO of C2N says, “Our mission is to translate exceptional science into unique diagnostics that can help as many people as possible. This blood test introduces a new option for patients, families and the medical community that have eagerly awaited innovative tools to address Alzheimer’s troubling problems.” 

GHR Foundation is partnering boldly with a consortium of government, industry, academic research and other philanthropists on a game-changing undertaking – the prevention of Alzheimer’s disease. Learn more here.  

0 Comments

    Categories

    All
    A4
    Alzheimer's
    Alzheimer's Association
    BridgeBuilder
    C2N
    Catholic Schools
    Children In Families
    COVID-19
    Develop Diagnostics
    DIAN Primary Prevention
    DIAN-TU
    Education
    Global Development
    Higher Education
    Inter-Religious Action
    La Jolla Institute
    Mayo Clinic
    Mayo Clinic Study Of Aging
    NIH-NIA
    Observational Studies
    Prepare The Future
    Prevention Trials
    Safeguarding
    Sister Support
    Twin Cities Racial Equity

    RSS Feed

CONNECT WITH US

NEWS  |  JOBS  | ​ CONTACT  
Privacy Policy  |  Terms of Use
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2023 GHR FOUNDATION
All Rights Reserved.